Table 1.
Clinical, biochemical, and virological characteristics of the studied group.
| Chronic liver disease (n = 41) | NDC (n = 10) | |||
|---|---|---|---|---|
| HCC | LC | PCH | ||
| No (%) | 15/41 (36.6%) | 16/41 (39.0%) | 10/41 (24.4%) | 10/10 (100%) |
| Gender (M/F) | 13/2 | 12/4 | 9/1 | 7/3 |
| Age (years) | 57.06 ± 12.58 (60.0) | 46.06 ± 7.9 (45.0) | 35.8 ± 5.2 (37.5) | 35.6 ± 3.1 (35.5) |
| Albumin (g/dL) | 4.22 ± 0.58 (4.3) | 4.15 ± 0.467 (4.0) | 4.5 ± 0.42 (4.6) | 3.83 ± 0.29 (3.85) |
| T. protein (g/dL) | 7.95 ± 0.603 (8.0) | 7.6 ± 0.67 (7.8) | 7.66 ± 0.49 (7.85) | 7.22 ± 0.53 (7.15) |
| T. bilirubin (mg/dL) | 1.69 ± 2.57 (1.2) | 1.28 ± 1.54 (1.0) | 0.99 ± 0.54 (0.9) | 0.57 ± 0.21 (0.55) |
| AST (μ/mL)∗ | 92.8 ± 65.67 (67.0) | 57.0 ± 26.6 (52.5) | 34.8 ± 11.44 (30.5) | 26.6 ± 5.5 (26.5) |
| ALT (μ/mL)∗∗ | 58.73 ± 36.86 (46.0) | 49.0 ± 17.35 (49.0) | 32.6 ± 14.8 (25.5) | 27.7 ± 4.1 (27.5) |
| Proth. time (Sec) | 14.3 ± 1.7 (14.0) | 13.58 ± 4.66 (14.6) | 13.2 ± 4.77 (13.3) | 6.04 ± 0.568 (6.1) |
| Proth. conc. (%) | 72.26 ± 13.78 (70.0) | 70.375 ± 12.99 (69.0) | 73.1 ± 19.0 (78.0) | 258.4 ± 14.06 (256.0) |
|
| ||||
| HCV infection | ||||
| Positive | 11/15 (73.3%) | 14/16 (87.5%) | 8/10 (80%) | 0/10 (0.0%) |
| Negative | 4/15 (26.7%) | 2/16 (12.5%) | 2/10 (20%) | 10/10 (100%) |
|
| ||||
| Tumor site | ||||
| Right lobe | 7/15 (46.7%) | |||
| Left lobe | 8/15 (53.3%) | |||
|
| ||||
| HCC grade | ||||
| Grade I | 2/15 (13.3%) | |||
| Grade II | 4/15 (26.7%) | |||
| Grade III | 9/15 (60.0%) | |||
|
| ||||
| Child score | ||||
| A | 3/15 (20.0%) | |||
| B | 6/15 (40.0%) | |||
| C | 6/15 (40.0%) | |||
Data expressed as mean ± SD (median).
Hepatocellular carcinoma (HCC), liver cirrhosis (LC), precirrhotic hepatitis (PCH), nondisease control (NDC).
∗Significant difference was detected between PCH and LC (P = 0.014) and HCC (P = 0.02).
∗∗Significant difference was detected between PCH and LC (P = 0.027) and HCC (P = 0.003).